Research ArticleRheumatoid Arthritis
Effectiveness of a Second Biologic After Failure of a Non–tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis
Katerina Chatzidionysiou, Merete Lund Hetland, Thomas Frisell, Daniela Di Giuseppe, Karin Hellgren, Bente Glintborg, Dan Nordström, Ritva Peltomaa, Kalle Aaltonen, Nina Trokovic, Eirik K. Kristianslund, Tore K. Kvien, Sella A. Provan, Bjorn Gudbjornsson, Gerdur Grondal, Lene Dreyer, Lars Erik Kristensen, Tanja Schjødt Jørgensen, Lennart T.H. Jacobsson and Johan Askling
The Journal of Rheumatology October 2021, 48 (10) 1512-1518; DOI: https://doi.org/10.3899/jrheum.201467
Katerina Chatzidionysiou
1K. Chatzidionysiou, MD, PhD, Associate Professor, T. Frisell, PhD, Associate Professor, D. Di Giuseppe, PhD, K. Hellgren, MD, PhD, J. Askling, MD, PhD, Professor, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;
Merete Lund Hetland
2M.L. Hetland, MD, PhD, Professor, B. Glintborg, MD, PhD, Associate Professor, DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, on behalf of the DANBIO Registry, Copenhagen, Denmark;
Thomas Frisell
1K. Chatzidionysiou, MD, PhD, Associate Professor, T. Frisell, PhD, Associate Professor, D. Di Giuseppe, PhD, K. Hellgren, MD, PhD, J. Askling, MD, PhD, Professor, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;
Daniela Di Giuseppe
1K. Chatzidionysiou, MD, PhD, Associate Professor, T. Frisell, PhD, Associate Professor, D. Di Giuseppe, PhD, K. Hellgren, MD, PhD, J. Askling, MD, PhD, Professor, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;
Karin Hellgren
1K. Chatzidionysiou, MD, PhD, Associate Professor, T. Frisell, PhD, Associate Professor, D. Di Giuseppe, PhD, K. Hellgren, MD, PhD, J. Askling, MD, PhD, Professor, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;
Bente Glintborg
2M.L. Hetland, MD, PhD, Professor, B. Glintborg, MD, PhD, Associate Professor, DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, on behalf of the DANBIO Registry, Copenhagen, Denmark;
Dan Nordström
3D. Nordström, MD, PhD, Professor, R. Peltomaa, MD, PhD, N. Trokovic, MS, Helsinki University and Hospital (ROB-FIN), Departments of Medicine and Rheumatology, Helsinki, Finland;
Ritva Peltomaa
3D. Nordström, MD, PhD, Professor, R. Peltomaa, MD, PhD, N. Trokovic, MS, Helsinki University and Hospital (ROB-FIN), Departments of Medicine and Rheumatology, Helsinki, Finland;
Kalle Aaltonen
4K. Aaltonen, MD, PhD, Pharmaceuticals Pricing Board, Ministry of Social Affairs and Health, Helsinki, Finland;
Nina Trokovic
3D. Nordström, MD, PhD, Professor, R. Peltomaa, MD, PhD, N. Trokovic, MS, Helsinki University and Hospital (ROB-FIN), Departments of Medicine and Rheumatology, Helsinki, Finland;
Eirik K. Kristianslund
5E.K. Kristianslund, MD, PhD, T.K. Kvien, MD, PhD, Professor, S.A. Provan, MD, PhD, Professor, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway;
Tore K. Kvien
5E.K. Kristianslund, MD, PhD, T.K. Kvien, MD, PhD, Professor, S.A. Provan, MD, PhD, Professor, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway;
Sella A. Provan
5E.K. Kristianslund, MD, PhD, T.K. Kvien, MD, PhD, Professor, S.A. Provan, MD, PhD, Professor, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway;
Bjorn Gudbjornsson
6B. Gudbjornsson, MD, PhD, Professor, Centre for Rheumatology Research, University Hospital, and Faculty of Medicine, University of Iceland, Reykjavik, Iceland;
Gerdur Grondal
7G. Grondal, MD, PhD, Professor, Department of Rheumatology and Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland;
Lene Dreyer
8L. Dreyer, MD, PhD, Professor, Department of Rheumatology, Aalborg University Hospital, and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark;
Lars Erik Kristensen
9L.E. Kristensen, MD, PhD, Professor, T.S. Jørgensen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark;
Tanja Schjødt Jørgensen
9L.E. Kristensen, MD, PhD, Professor, T.S. Jørgensen, MD, PhD, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark;
Lennart T.H. Jacobsson
10L.T. Jacobsson, MD, PhD, Professor, Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Johan Askling
1K. Chatzidionysiou, MD, PhD, Associate Professor, T. Frisell, PhD, Associate Professor, D. Di Giuseppe, PhD, K. Hellgren, MD, PhD, J. Askling, MD, PhD, Professor, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 48, Issue 10
1 Oct 2021
Effectiveness of a Second Biologic After Failure of a Non–tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis
Katerina Chatzidionysiou, Merete Lund Hetland, Thomas Frisell, Daniela Di Giuseppe, Karin Hellgren, Bente Glintborg, Dan Nordström, Ritva Peltomaa, Kalle Aaltonen, Nina Trokovic, Eirik K. Kristianslund, Tore K. Kvien, Sella A. Provan, Bjorn Gudbjornsson, Gerdur Grondal, Lene Dreyer, Lars Erik Kristensen, Tanja Schjødt Jørgensen, Lennart T.H. Jacobsson, Johan Askling
The Journal of Rheumatology Oct 2021, 48 (10) 1512-1518; DOI: 10.3899/jrheum.201467
Effectiveness of a Second Biologic After Failure of a Non–tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis
Katerina Chatzidionysiou, Merete Lund Hetland, Thomas Frisell, Daniela Di Giuseppe, Karin Hellgren, Bente Glintborg, Dan Nordström, Ritva Peltomaa, Kalle Aaltonen, Nina Trokovic, Eirik K. Kristianslund, Tore K. Kvien, Sella A. Provan, Bjorn Gudbjornsson, Gerdur Grondal, Lene Dreyer, Lars Erik Kristensen, Tanja Schjødt Jørgensen, Lennart T.H. Jacobsson, Johan Askling
The Journal of Rheumatology Oct 2021, 48 (10) 1512-1518; DOI: 10.3899/jrheum.201467